Journal for ImmunoTherapy of Cancer (Nov 2020)
605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models
Abstract
No abstracts available.